Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 50 of 305

Guidance and quality standards awaiting development
TitleType
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095Technology appraisal guidance
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma TS ID 11954Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823Technology appraisal guidance
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830Technology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Amivantamab with lazertinib for previously untreated locally advanced or metastatic non-small-cell lung cancer TS ID 11842Technology appraisal guidance
Amyotrophic lateral sclerosis - SAR443820 TS ID 11938Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Technology appraisal guidance
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Technology appraisal guidance
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable TS ID 11785Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidance
Avacincaptad pegol for treating late dry age-related macular degeneration ID6401Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6211]Technology appraisal guidance
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867Technology appraisal guidance
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma TS ID 11860Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine TS ID 11939Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment TS ID 11928Technology appraisal guidance
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma TS ID 11882Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All